Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul:163:103365.
doi: 10.1016/j.critrevonc.2021.103365. Epub 2021 May 27.

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis

Marco Tagliamento  1 , Elisa Agostinetto  2 , Marco Bruzzone  3 , Marcello Ceppi  3 , Kamal S Saini  4 , Evandro de Azambuja  5 , Kevin Punie  6 , C Benedikt Westphalen  7 , Gilberto Morgan  8 , Paolo Pronzato  9 , Lucia Del Mastro  10 , Francesca Poggio  11 , Matteo Lambertini  12
Affiliations
Meta-Analysis

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis

Marco Tagliamento et al. Crit Rev Oncol Hematol. 2021 Jul.

Abstract

Background: A systematic review and meta-analysis was performed to estimate mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection.

Methods: A systematic search of PubMed, up to 31 January 2021, identified publications reporting the case-fatality rate (CFR) among adult patients with solid or hematological malignancies and SARS-CoV-2 infection. The CFR, defined as the rate of death in this population, was assessed with a random effect model; 95% confidence intervals (CI) were calculated.

Results: Among 135 selected studies (N = 33,879 patients), the CFR was 25.4% (95% CI 22.9%-28.2%). At a sensitivity analysis including studies with at least 100 patients, the CFR was 21.9% (95% CI 19.1%-25.1%). Among COVID-19 patients with lung (N = 1,135) and breast (N = 1,296) cancers, CFR were 32.4% (95% CI 26.5%-39.6%) and 14.2% (95% CI 9.3%-21.8%), respectively.

Conclusions: Patients with solid or hematological malignancies and SARS-CoV-2 infection have a high probability of mortality, with comparatively higher and lower CFRs in patients with lung and breast cancers, respectively.

Keywords: Breast cancer; COVID-19; Cancer; Lung cancer; Mortality; SARS-CoV-2; Tumor.

PubMed Disclaimer

Figures

None
Graphical abstract
Fig. 1
Fig. 1
(A, B, C, D, E). Forest plot of studies reporting the CFR among patients with solid or hematological malignancies and SARS-CoV-2 infection. (A) Authors from A to C. (B) Authors from C to H. (C) Authors from H to M. (D) Authors from M to S. (E) Authors from S to Z. Abbreviations. CFR: case-fatality rate; 95% CI: 95% confidence interval.
Fig. 2
Fig. 2
(A, B). Forest plot of studies reporting the CFR among patients with lung cancer and SARS-CoV-2 infection. (A) Authors from A to M. (B) Authors from N to Z. Abbreviations. CFR: case-fatality rate; 95% CI: 95% confidence interval.
Fig. 3
Fig. 3
Forest plot of studies reporting the CFR among patients with breast cancer and SARS-CoV-2 infection. Abbreviations. CFR: case-fatality rate; 95% CI: 95% confidence interval.
See this image and copyright information in PMC

References

    1. Ali J., Sajjad K., Farooqi A.R., Aziz M.T., Rahat A., Khan S. COVID-19-positive cancer patients undergoing active anticancer treatment: an analysis of clinical features and outcomes. Hematol. Stem Cell Ther. 2020 doi: 10.1016/j.hemonc.2020.12.001. Published online December:S1658387620301801. - DOI - PMC - PubMed
    1. Alpert N., Rapp J.L., Marcellino B., Lieberman-Cribbin W., Flores R., Taioli E. Clinical course of cancer patients with COVID-19: a retrospective cohort study. JNCI Cancer Spectr. 2021;5(1) doi: 10.1093/jncics/pkaa085. pkaa085. - DOI - PMC - PubMed
    1. Angelis V., Tippu Z., Joshi K., et al. Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur. J. Cancer. 2020;136:99–106. doi: 10.1016/j.ejca.2020.06.027. - DOI - PMC - PubMed
    1. Antrim L., Capone S., Dong S., et al. Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. Cancer Treat. Res. Commun. 2021;26 doi: 10.1016/j.ctarc.2020.100273. - DOI - PMC - PubMed
    1. Aries J.A., Davies J.K., Auer R.L., et al. Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients. Br. J. Haematol. 2020;190(2) doi: 10.1111/bjh.16852. - DOI - PMC - PubMed